Home › All Companies › COGT

Cogent Biosciences, Inc. (COGT)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-05

Key Insights

  • Cogent Biosciences released Q1 2026 financial results on May 5, 2026, indicating continued operational activity and regular SEC compliance.
  • The filing is a standard 8-K for earnings announcement with no material agreements, leadership changes, or significant corporate events disclosed.
  • The press release content itself is not included in the 8-K filing document provided, limiting ability to assess specific financial performance, revenue trends, or guidance changes.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Quarterly Report Filed: 2026-05-05

Key Insights

  • The filing date of 2026-05-05 for Q1 2025 (ended 2025-03-31) represents a significant reporting delay, suggesting potential operational or administrative challenges that warrant investor scrutiny.
  • Multiple convertible debt and preferred stock instruments are present (Convertible Senior Notes Due 2031, Series A and B Non-Voting Convertible Preferred Stock), indicating capital structure complexity and potential dilution risk to common shareholders.
  • The presence of extensive stock-based compensation arrangements (employee stock purchase plans, stock options, restricted stock units with performance conditions) suggests substantial equity dilution ongoing, which may pressure EPS and shareholder value.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-04-03

Key Insights

  • Karen Jean Ferrante, a director of Cogent Biosciences, Inc. (COGT), was granted 686 stock options on April 1, 2026 as part of her director compensation package.
  • The options have an exercise price of $35.24 and will expire on April 1, 2036, aligning the director's interests with those of shareholders.
  • This insider transaction suggests continued confidence in the company's future prospects and alignment of management and board incentives.
Sentiment: Positive Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-03-31

Key Insights

  • Fairmount Funds Management LLC, a 10% owner of Cogent Biosciences, Inc. (COGT), converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of common stock on March 31, 2026.
  • Fairmount Healthcare Fund II LP, an entity affiliated with Fairmount Funds Management LLC, sold 7,000,000 shares of COGT common stock on March 31, 2026 at a price of $34.66 per share.
  • The reporting person, Fairmount Funds Management LLC, may be considered a director of COGT by deputization due to the fact that one of its managing members, Peter Harwin, serves on COGT's board of directors.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-02-17

Key Insights

  • Cogent Biosciences reported strong financial results for the year ended December 31, 2025, indicating continued growth and momentum in the business.
  • The press release suggests that the company is making progress on its key strategic initiatives and pipeline development, which could drive future value for investors.
  • However, the filing does not provide any specific forward-looking guidance or details on potential risks and challenges facing the company, which investors may want to monitor.
Sentiment: Positive Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-02-17

Key Insights

  • Cogent Biosciences, Inc. (COGT) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for cancer and other serious diseases. The company's lead product candidate, CGT9486, is in late-stage development for the treatment of advanced solid tumors.
  • The company has a diverse pipeline of early-stage preclinical and discovery programs targeting various disease areas, which could provide potential upside in the future.
  • Cogent Biosciences has secured a credit facility of up to $100 million to fund its ongoing operations and development activities, which should provide financial flexibility in the near term.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-22

Key Insights

  • Fairmount Funds Management LLC, a director and 10% owner of Cogent Biosciences, Inc. (COGT), has reported the sale of 3,500,000 shares of the company's common stock at $36.4 per share.
  • The sale represents a substantial portion of Fairmount's stake in Cogent, reducing its beneficial ownership from a previously higher level.
  • This transaction could signal a shift in Fairmount's investment strategy or portfolio allocation, which investors may want to monitor going forward.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-05

Key Insights

  • Karen Jean Ferrante, a director of Cogent Biosciences, Inc. (COGT), was granted 643 stock options on 01/01/2026 as part of her non-employee director compensation.
  • The options have an exercise price of $34.74 and will expire on 01/01/2036, indicating that Ferrante is incentivized to create long-term value for the company.
  • This insider transaction suggests that Ferrante, who is a director, has confidence in the company's future prospects and is aligning her interests with those of shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • The reporting person, John Edward Robinson, who is the Chief Scientific Officer of Cogent Biosciences, Inc., sold 90,000 shares of the company's common stock on December 26, 2025 at a weighted average price of $38.74.
  • The reporting person still holds 140,002 shares of the company's common stock following the reported transaction, which includes previously reported shares of common stock underlying restricted stock units granted to the reporting person.
  • The sale of 90,000 shares by the Chief Scientific Officer may indicate a reduction in his confidence or commitment to the company's long-term prospects.
Sentiment: Negative Significance: 6/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • Jessica Sachs, the Chief Medical Officer of Cogent Biosciences, Inc., sold 82,642 shares of the company's common stock on December 26, 2025 at a weighted average price of $38.70 per share.
  • Sachs still holds 133,938 shares of Cogent Biosciences, indicating she maintains a substantial ownership stake in the company.
  • The sale of shares by Sachs, a key executive, could signal potential changes or uncertainty within the company, which investors should monitor closely.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • The reporting person, John L. Green, who is the Chief Financial Officer of Cogent Biosciences, Inc., sold 77,000 shares of the company's common stock at a weighted average price of $38.68 per share.
  • This transaction reduces Green's direct beneficial ownership of Cogent Biosciences' common stock to 131,834 shares, indicating a reduction in his stake in the company.
  • The sale of shares by the CFO could suggest reduced confidence in the company's future performance or a need to raise personal funds, which may be viewed as a negative signal by investors.
Sentiment: Negative Significance: 6/10
View Original Filing →
Insider Trading Filed: 2025-12-30

Key Insights

  • Insider Evan Kearns, the Chief Legal Officer, sold 65,000 shares of Cogent Biosciences, Inc. (COGT) on 2025-12-26 at a weighted average price of $38.70 per share.
  • The sale represents a significant reduction in Kearns' beneficial ownership of COGT shares, which now stands at 109,398 shares.
  • Insider selling can sometimes signal a lack of confidence in the company's future prospects, so investors may want to monitor any further changes in Kearns' or other insiders' holdings.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.